Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 2Phase 1 1

Status

Unknown 2Withdrawn 1

Sponsor Class

OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Hydralazine × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00532818 2009-03-30

Hydralazine Valproate for Cervical Cancer

National Institute of Cancerología

Phase 3 Unknown
143 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00533299 2007-09-21

Hydralazine Valproate for Ovarian Cancer

National Institute of Cancerología

Phase 3 Unknown
211 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡